Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,204
archived clinical trials in
Healthy Studies

Treatment Of Patients With Social Anxiety Disorder
Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)
Status: Enrolling
Updated:  7/10/2017
GSK Investigational Site
mi
from
Miami, FL
Treatment Of Patients With Social Anxiety Disorder
Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)
Status: Enrolling
Updated: 7/10/2017
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Treatment Of Patients With Social Anxiety Disorder
Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)
Status: Enrolling
Updated:  7/10/2017
GSK Investigational Site
mi
from
Orlando, FL
Treatment Of Patients With Social Anxiety Disorder
Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)
Status: Enrolling
Updated: 7/10/2017
GSK Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
Treatment Of Patients With Social Anxiety Disorder
Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)
Status: Enrolling
Updated:  7/10/2017
GSK Investigational Site
mi
from
Smyrna, GA
Treatment Of Patients With Social Anxiety Disorder
Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)
Status: Enrolling
Updated: 7/10/2017
GSK Investigational Site
mi
from
Smyrna, GA
Click here to add this to my saved trials
Treatment Of Patients With Social Anxiety Disorder
Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)
Status: Enrolling
Updated:  7/10/2017
GSK Investigational Site
mi
from
Oakbrook Terrace, IL
Treatment Of Patients With Social Anxiety Disorder
Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)
Status: Enrolling
Updated: 7/10/2017
GSK Investigational Site
mi
from
Oakbrook Terrace, IL
Click here to add this to my saved trials
Treatment Of Patients With Social Anxiety Disorder
Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)
Status: Enrolling
Updated:  7/10/2017
GSK Investigational Site
mi
from
Rockville, MD
Treatment Of Patients With Social Anxiety Disorder
Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)
Status: Enrolling
Updated: 7/10/2017
GSK Investigational Site
mi
from
Rockville, MD
Click here to add this to my saved trials
Treatment Of Patients With Social Anxiety Disorder
Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)
Status: Enrolling
Updated:  7/10/2017
GSK Investigational Site
mi
from
Farmington Hills, MI
Treatment Of Patients With Social Anxiety Disorder
Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)
Status: Enrolling
Updated: 7/10/2017
GSK Investigational Site
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
Treatment Of Patients With Social Anxiety Disorder
Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)
Status: Enrolling
Updated:  7/10/2017
GSK Investigational Site
mi
from
Nutley, NJ
Treatment Of Patients With Social Anxiety Disorder
Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)
Status: Enrolling
Updated: 7/10/2017
GSK Investigational Site
mi
from
Nutley, NJ
Click here to add this to my saved trials
Treatment Of Patients With Social Anxiety Disorder
Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)
Status: Enrolling
Updated:  7/10/2017
GSK Investigational Site
mi
from
New York, NY
Treatment Of Patients With Social Anxiety Disorder
Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)
Status: Enrolling
Updated: 7/10/2017
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Treatment Of Patients With Social Anxiety Disorder
Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)
Status: Enrolling
Updated:  7/10/2017
GSK Investigational Site
mi
from
Media, PA
Treatment Of Patients With Social Anxiety Disorder
Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)
Status: Enrolling
Updated: 7/10/2017
GSK Investigational Site
mi
from
Media, PA
Click here to add this to my saved trials
Treatment Of Patients With Social Anxiety Disorder
Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)
Status: Enrolling
Updated:  7/10/2017
GSK Investigational Site
mi
from
Edmonton,
Treatment Of Patients With Social Anxiety Disorder
Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)
Status: Enrolling
Updated: 7/10/2017
GSK Investigational Site
mi
from
Edmonton,
Click here to add this to my saved trials
A Study to Assess the Metabolism, Excretion, and Mass Balance of Radio-Labeled Plazomicin
A Phase 1, Open-Label Study to Assess the Metabolism, Excretion, and Mass Balance of [14C]-Plazomicin Following a Single IV Infusion in Healthy Adult Male Subjects
Status: Enrolling
Updated:  7/11/2017
Clinical Site
mi
from
Lincoln, NE
A Study to Assess the Metabolism, Excretion, and Mass Balance of Radio-Labeled Plazomicin
A Phase 1, Open-Label Study to Assess the Metabolism, Excretion, and Mass Balance of [14C]-Plazomicin Following a Single IV Infusion in Healthy Adult Male Subjects
Status: Enrolling
Updated: 7/11/2017
Clinical Site
mi
from
Lincoln, NE
Click here to add this to my saved trials
Bioequivalence Study of Denosumab CP4 Drug Product and Commercially Available Denosumab CP2 Drug Product
A Double-Blind, Randomized, Single-Dose, Parallel-Group Study in Healthy Volunteers to Assess the Bioequivalence of a 120 mg Denosumab Subcutaneous Dose When Administered as Denosumab CP4 Drug Product or as Commercially Available Denosumab CP2 Drug Product
Status: Enrolling
Updated:  7/18/2017
Clinical Research Facility
mi
from
Cypress, CA
Bioequivalence Study of Denosumab CP4 Drug Product and Commercially Available Denosumab CP2 Drug Product
A Double-Blind, Randomized, Single-Dose, Parallel-Group Study in Healthy Volunteers to Assess the Bioequivalence of a 120 mg Denosumab Subcutaneous Dose When Administered as Denosumab CP4 Drug Product or as Commercially Available Denosumab CP2 Drug Product
Status: Enrolling
Updated: 7/18/2017
Clinical Research Facility
mi
from
Cypress, CA
Click here to add this to my saved trials
Bioequivalence Study of Denosumab CP4 Drug Product and Commercially Available Denosumab CP2 Drug Product
A Double-Blind, Randomized, Single-Dose, Parallel-Group Study in Healthy Volunteers to Assess the Bioequivalence of a 120 mg Denosumab Subcutaneous Dose When Administered as Denosumab CP4 Drug Product or as Commercially Available Denosumab CP2 Drug Product
Status: Enrolling
Updated:  7/18/2017
Clinical Research Facility
mi
from
San Antonio, TX
Bioequivalence Study of Denosumab CP4 Drug Product and Commercially Available Denosumab CP2 Drug Product
A Double-Blind, Randomized, Single-Dose, Parallel-Group Study in Healthy Volunteers to Assess the Bioequivalence of a 120 mg Denosumab Subcutaneous Dose When Administered as Denosumab CP4 Drug Product or as Commercially Available Denosumab CP2 Drug Product
Status: Enrolling
Updated: 7/18/2017
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects
A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects.
Status: Enrolling
Updated:  7/24/2017
Novo Nordisk Investigational Site
mi
from
Overland Park, KA
Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects
A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects.
Status: Enrolling
Updated: 7/24/2017
Novo Nordisk Investigational Site
mi
from
Overland Park, KA
Click here to add this to my saved trials
Evaluate Effects of Multiple Doses of Rifampin and Clarithromycin on the Single Dose Pharmacokinetics of Deflazacort
A Phase 1, Open-Label, 2-Arm, Fixed-Sequence Study to Evaluate the Potential Effects of Multiple Doses of Rifampin (CYP3A4 Inducer) and Clarithromycin (CYP3A4 Inhibitor) on the Single Dose Pharmacokinetics of Deflazacort in Healthy Subjects
Status: Enrolling
Updated:  8/2/2017
Celerion
mi
from
Tempe, AZ
Evaluate Effects of Multiple Doses of Rifampin and Clarithromycin on the Single Dose Pharmacokinetics of Deflazacort
A Phase 1, Open-Label, 2-Arm, Fixed-Sequence Study to Evaluate the Potential Effects of Multiple Doses of Rifampin (CYP3A4 Inducer) and Clarithromycin (CYP3A4 Inhibitor) on the Single Dose Pharmacokinetics of Deflazacort in Healthy Subjects
Status: Enrolling
Updated: 8/2/2017
Celerion
mi
from
Tempe, AZ
Click here to add this to my saved trials
Assessment of Whole Blood Cold Stored Platelets
Assessment of Whole Blood Cold Stored Platelets
Status: Enrolling
Updated:  8/3/2017
Puget Sound Blood Center
mi
from
Seattle, WA
Assessment of Whole Blood Cold Stored Platelets
Assessment of Whole Blood Cold Stored Platelets
Status: Enrolling
Updated: 8/3/2017
Puget Sound Blood Center
mi
from
Seattle, WA
Click here to add this to my saved trials
PK/PD and Safety/Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adults
Phase I Study to Evaluate Pharmacokinetics, Pharmacodynamics and Safety/Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Participants
Status: Enrolling
Updated:  8/3/2017
University of Illinois at Chicago
mi
from
Chicago, IL
PK/PD and Safety/Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adults
Phase I Study to Evaluate Pharmacokinetics, Pharmacodynamics and Safety/Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Participants
Status: Enrolling
Updated: 8/3/2017
University of Illinois at Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074
A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074 Monoclonal Antibody in HIV-infected and HIV-uninfected Individuals
Status: Enrolling
Updated:  8/7/2017
Rockefeller University
mi
from
New York, NY
A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074
A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074 Monoclonal Antibody in HIV-infected and HIV-uninfected Individuals
Status: Enrolling
Updated: 8/7/2017
Rockefeller University
mi
from
New York, NY
Click here to add this to my saved trials
A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074
A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074 Monoclonal Antibody in HIV-infected and HIV-uninfected Individuals
Status: Enrolling
Updated:  8/7/2017
University of Cologne
mi
from
Cologne,
A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074
A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074 Monoclonal Antibody in HIV-infected and HIV-uninfected Individuals
Status: Enrolling
Updated: 8/7/2017
University of Cologne
mi
from
Cologne,
Click here to add this to my saved trials
Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs as a Means of Predicting Drug-drug Interactions
The Effect of Multiple Doses of Cenobamate (YKP3089) on the Single Dose Pharmacokinetics of Cytochrome P450 Substrates (Midazolam, Warfarin, Omeprazole and Bupropion) Administered Orally in an Open-label, One-sequence Study in Healthy Subjects
Status: Enrolling
Updated:  8/7/2017
Vince and Associates Clinical Research
mi
from
Overland Park, KA
Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs as a Means of Predicting Drug-drug Interactions
The Effect of Multiple Doses of Cenobamate (YKP3089) on the Single Dose Pharmacokinetics of Cytochrome P450 Substrates (Midazolam, Warfarin, Omeprazole and Bupropion) Administered Orally in an Open-label, One-sequence Study in Healthy Subjects
Status: Enrolling
Updated: 8/7/2017
Vince and Associates Clinical Research
mi
from
Overland Park, KA
Click here to add this to my saved trials
Microvascular Flow Assessment Repeatability Study: The MARS Study
Microvascular Flow Assessment of the Periadventitial Adipose Tissue, Subcutaneous Adipose Tissue and Skeletal Muscle Using Contrast Enhanced Ultrasound (CEU); A Repeatability Study
Status: Enrolling
Updated:  8/10/2017
Clinical Translational Research Center
mi
from
Philadelphia, PA
Microvascular Flow Assessment Repeatability Study: The MARS Study
Microvascular Flow Assessment of the Periadventitial Adipose Tissue, Subcutaneous Adipose Tissue and Skeletal Muscle Using Contrast Enhanced Ultrasound (CEU); A Repeatability Study
Status: Enrolling
Updated: 8/10/2017
Clinical Translational Research Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
(+)-Alpha-Dihydrotetrabenazine Phase I
(+)-Alpha-Dihydrotetrabenazine Phase I
Status: Enrolling
Updated:  8/21/2017
University of Michigan Hospitals
mi
from
Ann Arbor, MI
(+)-Alpha-Dihydrotetrabenazine Phase I
(+)-Alpha-Dihydrotetrabenazine Phase I
Status: Enrolling
Updated: 8/21/2017
University of Michigan Hospitals
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method
A Single-Dose, Randomized, Double-Blind, Placebo-Controlled Onset-of-Action Study Utilizing the Double-Stopwatch Method
Status: Enrolling
Updated:  8/30/2017
University of Connecticut - Student Health Services
mi
from
Storrs, CT
Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method
A Single-Dose, Randomized, Double-Blind, Placebo-Controlled Onset-of-Action Study Utilizing the Double-Stopwatch Method
Status: Enrolling
Updated: 8/30/2017
University of Connecticut - Student Health Services
mi
from
Storrs, CT
Click here to add this to my saved trials
Single and Multiple Ascending Dose Pharmacokinetic Study of TR701 in Healthy Adults
A Double-Blind, Placebo and Active Controlled, Single and Multiple Rising Dose, Safety, Tolerance, and Pharmacokinetic Study of TR-701 in Normal Healthy Adults
Status: Enrolling
Updated:  8/30/2017
Covance Clinical Research Unit
mi
from
Madison, WI
Single and Multiple Ascending Dose Pharmacokinetic Study of TR701 in Healthy Adults
A Double-Blind, Placebo and Active Controlled, Single and Multiple Rising Dose, Safety, Tolerance, and Pharmacokinetic Study of TR-701 in Normal Healthy Adults
Status: Enrolling
Updated: 8/30/2017
Covance Clinical Research Unit
mi
from
Madison, WI
Click here to add this to my saved trials
A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects
Status: Enrolling
Updated:  8/31/2017
Clinical Research Facility
mi
from
Glendale, CA
A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects
Status: Enrolling
Updated: 8/31/2017
Clinical Research Facility
mi
from
Glendale, CA
Click here to add this to my saved trials
A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects
Status: Enrolling
Updated:  8/31/2017
Clinical Research Facility
mi
from
Baltimore, MD
A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects
Status: Enrolling
Updated: 8/31/2017
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers
A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of a Single Dose of Intravenous Ceftazidime NXL104 (3000/2000 mg) or Ceftaroline Fosamil NXL104 (1500/2000 mg), Compared With Placebo, Using Open-label Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers
Status: Enrolling
Updated:  8/31/2017
Clinical Research Facility
mi
from
Overland Park, KA
A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers
A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of a Single Dose of Intravenous Ceftazidime NXL104 (3000/2000 mg) or Ceftaroline Fosamil NXL104 (1500/2000 mg), Compared With Placebo, Using Open-label Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers
Status: Enrolling
Updated: 8/31/2017
Clinical Research Facility
mi
from
Overland Park, KA
Click here to add this to my saved trials
Positive Emotional Processing: Exploring Novel Treatment Targets in Social Phobia
Positive Emotional Processing: Exploring Novel Treatment Targets in Social Phobia - New Data
Status: Enrolling
Updated:  8/31/2017
University of California, San Diego; Psychiatry Clinical Research
mi
from
San Diego, CA
Positive Emotional Processing: Exploring Novel Treatment Targets in Social Phobia
Positive Emotional Processing: Exploring Novel Treatment Targets in Social Phobia - New Data
Status: Enrolling
Updated: 8/31/2017
University of California, San Diego; Psychiatry Clinical Research
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study to Investigate the Interaction Between JNJ-64155806 and Ethinylestradiol/Drospirenone in Healthy Females
A Phase 1, Open-label Study in Healthy Female Subjects to Investigate the Drug-drug Interaction Between JNJ-64155806 and Ethinylestradiol/Drospirenone
Status: Enrolling
Updated:  8/31/2017
Celerion
mi
from
Tempe, AZ
A Study to Investigate the Interaction Between JNJ-64155806 and Ethinylestradiol/Drospirenone in Healthy Females
A Phase 1, Open-label Study in Healthy Female Subjects to Investigate the Drug-drug Interaction Between JNJ-64155806 and Ethinylestradiol/Drospirenone
Status: Enrolling
Updated: 8/31/2017
Celerion
mi
from
Tempe, AZ
Click here to add this to my saved trials
Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Participants
A Double-blind, Double-dummy, Randomized, 3-Period Cross-over, Placebo- and Positive Controlled Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Subjects
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
Tempe, AZ
Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Participants
A Double-blind, Double-dummy, Randomized, 3-Period Cross-over, Placebo- and Positive Controlled Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Subjects
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
Tempe, AZ
Click here to add this to my saved trials
A Study of LY3009104(Baricitinib) for Healthy Subjects
A Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3009104 in Japanese Healthy Subjects
Status: Enrolling
Updated:  9/6/2017
Clinical Research Facility
mi
from
Honolulu, HI
A Study of LY3009104(Baricitinib) for Healthy Subjects
A Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3009104 in Japanese Healthy Subjects
Status: Enrolling
Updated: 9/6/2017
Clinical Research Facility
mi
from
Honolulu, HI
Click here to add this to my saved trials
PROS-2 Dose Response Effects of Exogenous Testosterone on the Prostate
Dose Response Effects of Exogenous Testosterone on the Prostate and Comparison With Effects on Body Composition (Short Title: PROS-2)
Status: Enrolling
Updated:  9/7/2017
Univ of Washington
mi
from
Seattle, WA
PROS-2 Dose Response Effects of Exogenous Testosterone on the Prostate
Dose Response Effects of Exogenous Testosterone on the Prostate and Comparison With Effects on Body Composition (Short Title: PROS-2)
Status: Enrolling
Updated: 9/7/2017
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Biological Basis of Individual Variation in Social Cooperation
The Biological Basis of Individual Variation in Social Cooperation
Status: Enrolling
Updated:  9/8/2017
Emory University Hospital
mi
from
Atlanta, GA
Biological Basis of Individual Variation in Social Cooperation
The Biological Basis of Individual Variation in Social Cooperation
Status: Enrolling
Updated: 9/8/2017
Emory University Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Biological Basis of Individual Variation in Social Cooperation
The Biological Basis of Individual Variation in Social Cooperation
Status: Enrolling
Updated:  9/8/2017
Emory University 1462 Clifton Rd
mi
from
Atlanta, GA
Biological Basis of Individual Variation in Social Cooperation
The Biological Basis of Individual Variation in Social Cooperation
Status: Enrolling
Updated: 9/8/2017
Emory University 1462 Clifton Rd
mi
from
Atlanta, GA
Click here to add this to my saved trials
CYP2B6 Genetics and Drug Interactions in Healthy Volunteers
Influence of Autoinhibition/Autoinduction and CYP2B6 Genetic Variations on CYP2B6 Activity and Drug Interactions in Healthy Volunteers
Status: Enrolling
Updated:  9/11/2017
Indiana University School of Medicine
mi
from
Indianapolis, IN
CYP2B6 Genetics and Drug Interactions in Healthy Volunteers
Influence of Autoinhibition/Autoinduction and CYP2B6 Genetic Variations on CYP2B6 Activity and Drug Interactions in Healthy Volunteers
Status: Enrolling
Updated: 9/11/2017
Indiana University School of Medicine
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Single-dose Study of [14C]Lorlatinib (PF-06463922) Metabolism In Healthy Male Volunteers
A Phase 1 Open-label, Radiolabeled, Single-dose Study To Investigate The Metabolism Of [14c]Lorlatinib (Pf-06463922) In Healthy Male Volunteers
Status: Enrolling
Updated:  9/11/2017
Covance Clinical Research Unit
mi
from
Madison, WI
Single-dose Study of [14C]Lorlatinib (PF-06463922) Metabolism In Healthy Male Volunteers
A Phase 1 Open-label, Radiolabeled, Single-dose Study To Investigate The Metabolism Of [14c]Lorlatinib (Pf-06463922) In Healthy Male Volunteers
Status: Enrolling
Updated: 9/11/2017
Covance Clinical Research Unit
mi
from
Madison, WI
Click here to add this to my saved trials
Alabama Veterans Rural Health Initiative
Alabama Veterans Rural Health Initiative
Status: Enrolling
Updated:  9/12/2017
Birmingham VAMC
mi
from
Birmingham, AL
Alabama Veterans Rural Health Initiative
Alabama Veterans Rural Health Initiative
Status: Enrolling
Updated: 9/12/2017
Birmingham VAMC
mi
from
Birmingham, AL
Click here to add this to my saved trials
Alabama Veterans Rural Health Initiative
Alabama Veterans Rural Health Initiative
Status: Enrolling
Updated:  9/12/2017
Tuscaloosa VAMC
mi
from
Tuscaloosa, AL
Alabama Veterans Rural Health Initiative
Alabama Veterans Rural Health Initiative
Status: Enrolling
Updated: 9/12/2017
Tuscaloosa VAMC
mi
from
Tuscaloosa, AL
Click here to add this to my saved trials
A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%
Status: Enrolling
Updated:  9/13/2017
Andover Eye Associates
mi
from
Andover, MA
A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%
Status: Enrolling
Updated: 9/13/2017
Andover Eye Associates
mi
from
Andover, MA
Click here to add this to my saved trials
Study of Pharmacokinetics of a Single IV Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Subjects
A Phase 1, Non-randomized, Parallel-group, Open-label Study to Characterize the Pharmacokinetics of a Single Intravenous Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Subjects
Status: Enrolling
Updated:  9/13/2017
Clinical Research Facility
mi
from
Minneapolis, MN
Study of Pharmacokinetics of a Single IV Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Subjects
A Phase 1, Non-randomized, Parallel-group, Open-label Study to Characterize the Pharmacokinetics of a Single Intravenous Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Subjects
Status: Enrolling
Updated: 9/13/2017
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Communication & Peer Support Effects on Physical Activity in Overweight Postmenopausal Women
A Feasibility Study on the Effects of Tailored Communication and Health Coach Support on Physical Activity in Overweight Postmenopausal Women: BePHIT
Status: Enrolling
Updated:  9/13/2017
Ohio State University Medical Center
mi
from
Columbus, OH
Communication & Peer Support Effects on Physical Activity in Overweight Postmenopausal Women
A Feasibility Study on the Effects of Tailored Communication and Health Coach Support on Physical Activity in Overweight Postmenopausal Women: BePHIT
Status: Enrolling
Updated: 9/13/2017
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Microdialysis and Pharmacokinetic Study of TR-701
An Open Label, Single Dose, Microdialysis and Pharmacokinetic Study of TR-701 in Normal Healthy Adults
Status: Enrolling
Updated:  9/21/2017
General Clinical Research Center
mi
from
Gainesville, FL
Microdialysis and Pharmacokinetic Study of TR-701
An Open Label, Single Dose, Microdialysis and Pharmacokinetic Study of TR-701 in Normal Healthy Adults
Status: Enrolling
Updated: 9/21/2017
General Clinical Research Center
mi
from
Gainesville, FL
Click here to add this to my saved trials
A Study Comparing Amounts of Tafamidis (PF‑06291826) in the Blood Without Food in Healthy Volunteers
A Phase 1, Open‑Label, Three‑Period Randomized, Single Dose Study To Estimate The Relative Bioavailability Of Pf‑06291826 (Tafamidis) Free Acid Capsule Formulation Versus Commercial Capsule In Healthy Subjects Under Fasted Conditions
Status: Enrolling
Updated:  9/26/2017
Pfizer New Haven Clinical Research Unit
mi
from
New Haven, CT
A Study Comparing Amounts of Tafamidis (PF‑06291826) in the Blood Without Food in Healthy Volunteers
A Phase 1, Open‑Label, Three‑Period Randomized, Single Dose Study To Estimate The Relative Bioavailability Of Pf‑06291826 (Tafamidis) Free Acid Capsule Formulation Versus Commercial Capsule In Healthy Subjects Under Fasted Conditions
Status: Enrolling
Updated: 9/26/2017
Pfizer New Haven Clinical Research Unit
mi
from
New Haven, CT
Click here to add this to my saved trials
Fiber Health Benefits
Health Benefits and Tolerance of Dietary Fiber Supplements in Children
Status: Enrolling
Updated:  9/26/2017
University of Iowa
mi
from
Iowa City, IA
Fiber Health Benefits
Health Benefits and Tolerance of Dietary Fiber Supplements in Children
Status: Enrolling
Updated: 9/26/2017
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Feasibility of the BREATHE Asthma Intervention Trial
Self-care Decision-making: Feasibility of the BREATHE Asthma Intervention Trial
Status: Enrolling
Updated:  9/29/2017
Spectrum Health Services
mi
from
Philadelphia, PA
Feasibility of the BREATHE Asthma Intervention Trial
Self-care Decision-making: Feasibility of the BREATHE Asthma Intervention Trial
Status: Enrolling
Updated: 9/29/2017
Spectrum Health Services
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Feasibility of the BREATHE Asthma Intervention Trial
Self-care Decision-making: Feasibility of the BREATHE Asthma Intervention Trial
Status: Enrolling
Updated:  9/29/2017
Greater Philadelphia Health Action
mi
from
Philadelphia, PA
Feasibility of the BREATHE Asthma Intervention Trial
Self-care Decision-making: Feasibility of the BREATHE Asthma Intervention Trial
Status: Enrolling
Updated: 9/29/2017
Greater Philadelphia Health Action
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season
A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults
Status: Enrolling
Updated:  10/2/2017
Clinical Research Facility
mi
from
South Miami, FL
Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season
A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults
Status: Enrolling
Updated: 10/2/2017
Clinical Research Facility
mi
from
South Miami, FL
Click here to add this to my saved trials
Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season
A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults
Status: Enrolling
Updated:  10/2/2017
Clinical Research Facility
mi
from
Stockbridge, GA
Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season
A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults
Status: Enrolling
Updated: 10/2/2017
Clinical Research Facility
mi
from
Stockbridge, GA
Click here to add this to my saved trials
Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season
A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults
Status: Enrolling
Updated:  10/2/2017
Clinical Research Facility
mi
from
Portland, OR
Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season
A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults
Status: Enrolling
Updated: 10/2/2017
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of Lasmiditan in Healthy Participants
Effect of Age on the Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Healthy Subjects
Status: Enrolling
Updated:  10/2/2017
Covance-Daytona Beach
mi
from
Daytona Beach, FL
A Study of Lasmiditan in Healthy Participants
Effect of Age on the Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Healthy Subjects
Status: Enrolling
Updated: 10/2/2017
Covance-Daytona Beach
mi
from
Daytona Beach, FL
Click here to add this to my saved trials